Denosumab (Prolia) is a therapy for osteoporosis that can be effective in selected patients with osteoporosis. Denosumab is a fully human antibody against RANKL (RANK Ligand, or Receptor Activator of Nuclear factor Kappa B Ligand). RANKL is produced by osteoblasts and is important in osteoclast differentiation. Its removal reduces osteoclastic activity and bone resorption.

To read more or access our algorithms and calculators, please log in or register.